Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early and late onset breast carcinoma by Sinha, Satyabrata et al.
BioMed CentralMolecular Cancer
ssOpen AcceResearch
Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at 
chromosomal 9q22.3 region: Pathological significance in early- and 
late-onset breast carcinoma
Satyabrata Sinha1, Ratnesh K Singh1, Neyaz Alam2, Anup Roy3, 
Susanta Roychoudhury4 and Chinmay Kumar Panda*1
Address: 1Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India, 2Department of Surgical Oncology, 
Chittaranjan National Cancer Institute, Kolkata, India, 3Department of Pathology, Medical College, Kolkata, India and 4Molecular and Human 
Genetics Division, Indian Institute of Chemical Biology, Kolkata, India
Email: Satyabrata Sinha - satyabratasinha@gmail.com; Ratnesh K Singh - ratnein@gmail.com; Neyaz Alam - humpty78in@yahoo.co.in; 
Anup Roy - anuproy@vsnl.net; Susanta Roychoudhury - susanta@iicb.res.in; Chinmay Kumar Panda* - ckpanda.cnci@gmail.com
* Corresponding author    
Abstract
Introduction: Younger women with breast carcinoma (BC) exhibits more aggressive pathologic features
compared to older women; young age could be an independent predictor of adverse prognosis. To find any
existing differences in the molecular pathogenesis of BC in both younger and older women, alterations at
chromosomal (chr.) 9q22.32-22.33 region were studied owing to its association in wide variety of tumors. Present
work focuses on comparative analysis of alterations of four candidate genes; PHF2, FANCC, PTCH1 and XPA
located within 4.4 Mb region of the afore-said locus in two age groups of BC, as well as the interrelation and
prognostic significance of alterations of these genes.
Methods: Deletion analysis of PHF2, FANCC, PTCH1 and XPA were examined in a subset of 47 early-onset
(group-A: ≤ 40 years) and 59 late-onset (group-B: > 40 years) breast carcinomas using both microsatellite and
exonic markers. Methylation Sensitive Restriction analysis (MSRA) was done to check for promoter methylation.
Quantitative real-time polymerase chain reaction (Q-PCR) and immunohistochemisty (IHC) was done in some
genes to see their relative mRNA and protein expressions respectively. Clinico-pathological correlation of
different parameters as well as patient survival was calculated using different statistical softwares like EpiInfo
6.04b, SPSS 10.0 etc.
Results: Either age group exhibited high frequency of overall alterations in PHF2, FANCC and PTCH1 compared
to XPA. Samples with alteration (deletion/methylation) in these genes showed reduced level of mRNA expression
as seen by Q-PCR. Immunohistochemical analysis of FANCC and PTCH1 also supported this observation. Poor
patient survival was noted in both age groups having alterations in FANCC. Similar result was also seen with
PTCH1 and XPA alterations in group-A and PHF2 alterations in group-B. This reflected their roles as prognostic
tools in the respective groups in which they were altered.
Conclusion: Overall alterations of PHF2, FANCC and PTCH1 were comparatively higher than XPA. Differential
association of alterations in FANCC and PTCH1 with that of PHF2, XPA and two breast cancer susceptibility
genes (BRCA1/BRCA2) in the two age groups suggests differences in their molecular pathogenesis and
dysregulation of multiple DNA repair pathways as well as hedgehog dependent stem cell renewal pathway.
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Breast carcinoma (BC) is the second leading cause of can-
cer deaths and the most common cancer among women.
About 23% of urban women in eastern India are affected
by this disease [1]. Depending on age at onset, BC can be
early-onset (≤ 40 years) and late-onset (> 40 years) type.
However, the cut-off value for early-onset BC varies
among investigators, ranging from 35–50 years. Signifi-
cant differences in clinico-pathological features like large
tumor size of higher grade, presence of positive lymph
nodes, absence of steroid receptors, and high S-phase frac-
tion in younger women with BC indicated altered biology
and pathogenesis between these two groups of BC [2-4].
Another report showed that in Asian population, BC
patients below 40 years have tumors with a poorer prog-
nostic profile. However, this did not translate into a
poorer overall survival, and this might be attributable to
more aggressive adjuvant treatment of younger patients
[5]. All these reports suggested early-onset BC to be a bio-
logically separate disease and independently predict more
adverse outcomes. Thus, the molecular analysis of BC in
the two age groups is pertinent to understand the differ-
ences in pathogenesis, if any. Our earlier studies on chro-
mosomes (chrs.) 1p/q, 9p and 11p/q showed differential
pattern of molecular alterations between the two age
groups of BC [3-6]. In order to understand the pathogen-
esis in detail our aim is to analyze the alterations in other
chromosomal regions which showed frequent alterations
in BC.
Cytogenetic analyses have revealed a variety of chromo-
somal aberrations at chr.9q22 in different malignancies
including BC [7]. Comparative genomic hybridization
(CGH) and flow-cytometric analyses also showed losses
at chr.9q in BC [8-10]. Studies in basal cell carcinoma
(BCC), squamous cell carcinoma (SCC) as well as blad-
der, prostate, esophageal and blood cancer detected fre-
quent loss of heterozygosity (LOH) at chr.9q22.3 [11,12].
Significant correlation between losses of chr.9q22.3 with
lymph node metastasis in BC is reported [13].
Chr.9q22.3 is a relatively broad region (8.71 Mb) harbor-
ing several putative tumor suppressor genes (TSGs). We
focused primarily on a 4.4 Mb region between the
chr.9q22.32-22.33 where DNA-damage repair genes like
FANCC (Fanconi anaemia Complementation-group C),
XPA (Xeroderma Pigmentosum A) as well as the hedgehog
(HH) pathway associated gene PTCH1 (human homologue
of Drosophila patched gene) are localized [13-16]. FANCC
localized at chr.9q22.32 (96.89 Mb from p-ter) is associ-
ated with reconstitutive and self-renewal potential of hae-
matopoietic stem cells [17,18]. Its ablation leads to
increased sensitivity to DNA crosslinking agents, loss of
FANCD2 activation, and impaired homologous recombi-
nation due to poor functioning of the BRCA1-BRCA2-
NBS1-RAD51 mediated DNA repair [19]. Deletion of
FANCC in bladder carcinoma, mutations in young-onset
pancreatic cancer and Fanconi Anaemia-C patients, and
down-regulation in head and neck squamous cell carci-
noma (HNSCC) are reported [16,20-22]. PTCH1 (350 Kb
downstream to FANCC) is a key regulator in stem cell
renewal hedgehog signaling pathway and functions as a
tumor suppressor by inhibiting G1-S and G2-M phases of
cell cycle. PTCH1 has been implicated in the development
of medulloblastomas, glioblastomas, rhabdomyosarco-
mas, pancreatic cancers, and other soft tissue tumors [23].
A recent report suggested loss of PTCH1 in 19% of human
breast cancers, and 33% of breast cancer cell lines [9].
Mutations in PTCH1 gene have been reported in nevoid
basal cell carcinoma syndrome (NBCCS), familial BC and
its loss induced tumor progression in basal cell carcinoma
(BCC) [24,25]. Furthermore, immunohistochemical anal-
ysis showed reduced expression of PTCH1 due to pro-
moter methylation in BC [26]. XPA (2.23 Mb down-
stream of PTCH1) gene is essential for assembly of the
pre-incision complex during the processing of DNA dam-
age via the nucleotide excision repair (NER) pathway [27-
29]. Defects in NER are associated with several human
autosomal recessive hereditary disorders, such as xero-
derma pigmentosum and a marked predisposition to skin
cancer (early BCC, SCC and melanoma); early internal
tumors [30]. LOH in sporadic ovarian, colon, lung carci-
nomas and significant association between oral premalig-
nant lesions and polymorphism of XPA are reported
[31,32]. PHF2, a novel transcriptional regulatory gene
associated with hereditary sensory neuropathy type 1
(HSN1) has also been identified at chr.9q22.32, 1.52 Mb
upstream of FANCC [33]. However, its role in tumorigen-
esis is not yet well understood.
Thus, it is evident that alterations of these genes together
could cumulatively increase genetic instability and cellu-
lar proliferation. Furthermore, study of co-alterations of
these genes could be useful in diagnosis and prognosis of
a disease. Thus an attempt was made in this study to ana-
lyze the alterations (deletion, methylation and expres-
sion) of PHF2, FANCC, PTCH1 and XPA in early- and late-
onset BC of Indian patients and correlate them with clin-
ico-pathological differences.
Methods
Patients, Tumor tissues and cell lines
One hundred six invasive breast carcinomas (BC) and
their corresponding normal tissues or peripheral blood
leukocytes (PBL) were randomly collected from 104 unre-
lated patients, undergoing surgery at the hospital of Chit-
taranjan National Cancer Institute, Kolkata, India and
stored at -80°C over a period of 9 years (1999–2007). The
BC samples were segregated into early-onset BC (group-A:
≤ 40 years) and late-onset BC (group-B: > 40 years)Page 2 of 13
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Informed consent from patients and Research Ethics
Committee of the institute were obtained. All these
tumors were graded and staged according to UICC TNM
classification [34]. Detailed clinico-pathological histories
of the patients are presented in Table 1. Part of the freshly
operated tissues was directly collected in TRIzol reagent
(Invitrogen, USA) for RNA isolation and the rest for DNA
extraction. The BC cell line MCF-7 was obtained from
American Type Culture Collection and grown according
to ATCC instructions.
Microdissection and DNA Extraction
Contaminant normal cells in the samples were removed
by manual microdissection from cryosections (5 μm)
using surgical knives under a dissecting microscope [Leica
MZ 16]. The representative sections from different regions
of the specimens were stained with hematoxylin-eosin for
diagnosis as well as for marking of tumor-rich regions.
The microdissected samples containing at least 70–80%
tumor cells were taken for DNA isolation via proteinase-K
digestion, followed by phenol/chloroform extraction pro-
cedure [35].
Deletion analysis of the candidate TSGs
Deletion analysis of the candidate genes was done using 6
microsatellite markers in the following order: Centro-
mere- (PHF2: D9S1803, D9S197, D9S196), (FANCC:
D9S1958), (PTCH1: D9S1816) and (XPA: D9S1714) –
Telomere, selected on the basis of their map positions and
heterozygosity (Ensembl release 44; Genome Database).
One exonic marker each from PHF2 exon-18 and FANCC
exon-2 were designed using Primer3Input 0.4.0 software
to see the homozygous/hemizygous deletion (HD/HED)
status of these genes [Table 2].
To detect for deletion in informative microsatellite mark-
ers, standard polymerase chain reaction (PCR) analysis
with [γ-p32] ATP end labeled forward primer was done in
a 20 μl reaction volume as described previously [35,36].
Multiplex PCR was done to see deletion (HD/HED) in the
non-informative markers [35]. The D9S104 marker at
chr.9p13 was used as control (CL) due to low frequency
of alterations seen in BC (data not shown). The PCR prod-
ucts were run on 2% agarose gel, stained with ethidium
bromide and visualized under UV transluminator.
Using a densitometric scanner (Bio-Rad GS-800, USA) the
number of alleles at LOI (locus of interest) was deter-
mined from the signal intensities according to the follow-
ing formula:
Where T = tumor DNA; N = normal DNA; CL = Control;
LOI = Locus of Interest
Allelic values of ≤ 0.5, 0.9 – 1.7, ≥ 1.8 to < 5.0 and > 5.0
will be considered as homozygous deletion (HD),
hemizygous deletion (HED), retention of homozygosity
(RA) and amplification of the alleles respectively [37].
Allele Number
LOI T CL T
LOI N CL N
= ×2 ( ) / ( )
( ) / ( )
Table 1: Clinico-pathological parameters of early- and late-onset BC
Group A Group B
Clinical features Case Mean age (years) Age range (years) Case Mean age (years) Age range (years)
Histological Type
Ductal 45 34 25–40 59 53 41–77
Lobular 2 28 20–35 0 _ _
Clinical Stage
TNM Stage I 1 40 40 2 48 45–50
TNM Stage II 7 33 23–40 21 51 42–61
TNM Stage III 36 35 20–40 33 53 41–77
TNM Stage IV 3 37 36–38 3 57 48–72
Tumor Differentiation
Grade 1 4 32 20–40 8 52 43–61
Grade 2 32 33 18–40 39 47 41–42
Grade 3 11 38 33–40 12 56 42–77
Lymph Node
Positive 33 35 26–40 48 52 42–77
Negative 14 31 18–40 11 51 41–65Page 3 of 13
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(MSRA)
Promoter methylation of PHF2, FANCC, PTCH1 and XPA
were done in all BC samples by MSRA using methyl-sensi-
tive restriction enzyme HpaII and its methylation in-sen-
sitive iso-schizomer MspI [38]. Primer sequences are
listed in Table 2. Promoter region of PTCH1 gene har-
bored 6 CCGG-recognition sites for the above restriction
enzymes while, there were two CCGG sites in FANCC pro-
moter and one each in PHF2 and XPA gene promoters.
The 445-bp fragment of β-3A adaptin gene (K1) and 229-
bp fragment of RARβ2 exon-1 (K2) was used as digestion
and integrity controls respectively [39].
Mutation analysis
Mutation analysis of exon-23 of PTCH1 was done in 60
BC samples by single strand conformation polymorphism
(SSCP) analysis using [α-p32] dCTP as described previ-
ously [36]. Two primers from exon 23 (Ex*23 and Ex-23)
were designed to cover the entire exon-23 which is a muta-
tional hotspot and reported to be mutated in a variety of
cancers [Table 2]. Sequencing for both strands of the sam-
ples showing abnormal band shift in autoradiographs
were done using 3100-Avant Genetic Analyzer (PE
Applied Biosystems Inc, USA).
Quantitative Real-time PCR (Q-PCR)
The mRNA expression of PHF2, FANCC, PTCH1 and XPA
in normal breast tissue (n = 6), and primary BC (n = 14)
and 1 cell line (MCF-7) was analyzed by quantitative real-
time (Q-PCR). Total RNA was isolated from samples
using TRIzol reagent according to the manufacturer's pro-
tocol (Ambion Inc.). Complementary-DNA (cDNA) was
synthesized from 1 μg total RNA using Random hexamer
(Invitrogen, USA) and Superscript III (Invitrogen, USA)
according to manufacturer's protocol. PCR was performed
in 40 cycles on an ABI Prism 7500 using Power SYBR
Green PCR Master Mix (Applied Biosystems, USA) in a
final volume of 15 μl. Each sample was run in triplicates
and average value was considered for analysis. Relative
quantities (ΔΔCt) were obtained by normalization against
human beta2-microglobulin gene [40]. Primers are listed
in Table 2.
Immunohistochemistry
Immunostaining of FANCC and PTCH1 protein were
done in 20 primary breast carcinomas using the Avidin-
Biotin-Peroxidase Complex (ABC) staining kit according
to manufacturers protocol (Santa Cruz Biotechnology,
CA, USA). About 3–5 μm paraffin sections were de-par-
affinized, rehydrated and reacted overnight with primary
antibodies (goat polyclonal IgG, sc-18110 for FANCC (C-
14) and sc-6149 for PTCH1 (G-19); Santa Cruz, CA, USA)
at a dilution of 1:100 at 4°C. Horse-Radish-Peroxidase
conjugated rabbit anti-goat secondary antibody (sc-2768)
was added at 1:500 dilutions. The slides were developed
using 3-3' diaminobenzidine (DAB) as the chromogen
and counterstained with hematoxylin. The staining inten-
sity (- = negative, + = weak, 2+ = moderate, and 3+ =
strong) and the percentage of positive cells (- = 0%, + = 1–
24%, 2+ = 25–49%, and 3+ = 50–100%) were evaluated
by two observers independently [41].
Statistical Analysis of Clinical Data
Fisher's exact test was used to determine the association
between tumors genetic profile and different clinico-path-
ological features. Survival analysis was performed accord-
ing to Kaplan-Meier method. Post-operative overall
survival was measured from the date of surgery to the date
of last follow-up or death (up to 5 years). Probability
value (P-value) ≤ 0.05 was considered statistically signifi-
cant. All the statistical analysis was performed using statis-
tical programs EpiInfo 6.04b, SPSS 10.0 (SPSS Inc.
Chicago, IL, USA).
Table 2: Summary of oligonucleotides
Primers Location Analytical 
purpose
Forward Primer Reverse Primer Size (bp)
PHF2 Ex-18 9q22.32 HD/HED 5'-ACTCCTGCCTGCAGACCAC-3' 5'-CCTGCTCTTCCTCGTAGTCG-3' 168
FANCC Ex-2 9q22.32 HD/HED 5'-TGGCTCAAGATTCAGTAGATCTTTC-3' 5'-TTTCAAGGCTTCATACATCTTCC-3' 158
PHF2 promoter -893 to -670 region Methylation 5'-GTGGTGTCCCAACCAGAAAC-3' 5'-GGGACCCCGAGGATAAGATA-3' 223
FANCC promoter -319 to -144 region Methylation 5'-TTTTACCCCGTTGACAAAGC-3' 5'-CGGTACTGCTCCAGTGTTCC-3' 175
PTCH1 promoter -715 to -420 region Methylation 5'-CGAGGAGCACAAGAAAGCAG-3' 5'-AGAAAGAGCCAGCGAATCC-3' 295
XPA promoter Ex.1 -126 to +56 region Methylation 5'-AGGCGCTCTCACTCAGAAAG-3' 5'-TCCGCGGGTTGCTCTAAA-3' 182
PTCH1 Ex.*23 Intron 22–23 to Ex.23 SSCP 5'-TCTAACCCACCCTCACCCTC-3' 5'-ATTGCTAGGGCCAGAATGCC-3' 226
PTCH1 Ex.23 Ex.23 to Intron 23–24 SSCP 5'-TTCTGCCTCCGTGACTGTC-3' 5'-CTCTAGGTCCCTTGGCTGC-3' 265
PHF2 Ex. 18–19 Coding regions of exons Q-PCR 5'-ACTCCTGCCTGCAGACCAC-3' 5'-TCGACCGGGACTTAAAGATG-3' 257
FANCC Ex. 7–8 Coding regions of exons Q-PCR 5'-TGGAGGCTCTCCTCATCTGT-3' 5'-GCATTCGATCCTTCTCAGACA-3' 223
PTCH1 Ex. 1–2 Coding regions of exons Q-PCR 5'-GACCGGGACTATCTGCA-3' 5'-GAGGAGGCCCACAACC-3' 186
β2 Microglobulin 15q21-q22.2 Q-PCR 5'-GTGCTCGCGCTACTCTCTCT-3' 5'-TCAATGTCGGATGGATGAAA-3' 153
β-3A-adaptin (K1*) 5q14.1 DNA cleavage 
control
5'-TGCCCTCTGGACTGGAACCT-3' 5'-CCTGAGCCCAGCCCAAGTC-3' 445
RARβ2 (K2**) 3p24.2 DNA integrity 
control
5'-AGAGTTTGATGGAGTTGGGT-3' 5'-CATTCGGTTTGGGTCAATCC-3' 229Page 4 of 13
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Deletion analysis of candidate TSGs loci
Deletion mapping identified LOH in microsatellite mark-
ers and both hemi/homozygous deletion in the exonic
markers [Figure 1]. Compared to XPA, high deletion was
seen in the PHF2, FANCC and PTCH1 loci in both age
groups of BC [Figure 2; Additional Files 1 and 2]. Order of
deletion frequencies were: group-A: FANCC (47%) >
PHF2 (43%) > PTCH1 (30%) > XPA (21%) and group-B:
FANCC (49%) > PHF2 (42%) > PTCH1 (27%) > XPA
(20%). LOH was concordant with hemizygous deletion in
exonic markers. Homozygous deletions were restricted to
(a) Representative autoradiograph showing loss of heterozygosity (LOH) (b) homozygous/hemizygous deletion (HD/HED) analysis in microsatellite markers (c) HD/HED of exonic markers.Figure 1
(a) Representative autoradiograph showing loss of heterozygosity (LOH) (b) homozygous/hemizygous dele-
tion (HD/HED) analysis in microsatellite markers (c) HD/HED of exonic markers. → indicates loss of correspond-
ing alleles.Page 5 of 13
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Pattern of deletion at different chr..9q22.32-22.33 markers in early- and late-onset BCFigu e 2
Pattern of deletion at different chr.9q22.32-22.33 markers in early- and late-onset BC.
Molecular Cancer 2008, 7:84 http://www.molecular-cancer.com/content/7/1/84PHF2 exon-18 and FANCC exon-2. Interstitial deletion or
loss of entire region was observed in 32% (15/47) group-
A and 42% (25/59) group-B samples indicating the
importance of this region in BC.
Deletion between PTCH1 and XPA was significantly asso-
ciated in both group-A (P = 0.02) and group-B (P =
0.00003) [Table 3].
Promoter Methylation analysis
Comparable frequencies of promoter methylation were
observed in both age groups. In group-A, PTCH1 exhib-
ited highest 32% methylation followed by FANCC (30%),
PHF2 (21%) and XPA (17%). Contrastingly, in group-B,
FANCC showed highest 39% methylation followed by
36% in PTCH1, 24% in XPA and 22% in PHF2 [Figure 3;
Additional File 3]. Concomitant methylation in all the
candidate genes was observed in two early-onset and five
late-onset BC samples.
Significant association was observed between methyla-
tion of FANCC and PHF2 in both group-A (P = 0.02) and
group-B (P = 0.001). Methylation of XPA was significantly
associated with methylation of PHF2 (P = 0.03) and
FANCC (P = 0.0001) in group-A and that of PTCH1 (P =
0.01) in group-B [Table 4]. In FANCC, both deletion and
methylation showed significant association in both
groups (P = 0.004 and 0.002) while, in PTCH1 significant
association was observed only in group-A (P = 0.002)
[data no shown].
Mutation analysis of PTCH1 Exon-23
SSCP analysis in 60 primary BC samples revealed no
abnormal band shifts in PTCH1 exon-23. Direct sequenc-
ing of 20 out of these 60 samples showed no changes in
the nucleotide sequences.
Association between overall alterations of candidate TSGs
Either deletion or methylation of any one of the 4 candi-
date genes were seen in about 91% of the samples in both
groups indicating the importance of chr.9q22.32-22.33 in
the development of BC. Overall alterations (deletion/
methylation) of PHF2, FANCC, PTCH1 and XPA were
comparable in both age groups, them showing 60%, 53%,
43% and 36% alterations respectively in group-A and
59%, 59%, 58% and 36% in group-B (Figure 4; Addi-
tional File 4). Overall alterations of PTCH1 showed signif-
icant association with XPA in both group-A (P = 0.003)
and group-B (P = 0.007). However, overall alterations of
PHF2 showed significant association with either FANCC
(P = 0.005) or XPA (P = 0.05) only in group-B [data not
shown].
Expression analysis of the candidate genes
Q-PCR analysis of PHF2, FANCC and PTCH1 mRNA
revealed reduced mRNA expression of in all these genes.
In respect to non-tumor control, relative fold reduction in
Table 3: Association between deletions of the 4 candidate genes in early- and late-onset BC
Group-A Group-B
PHF2 FANCC PTCH1 XPA PHF2 FANCC PTCH1 XPA
D+ D- D+ D- D+ D- D+ D- D+ D- D+ D- D+ D- D+ D-
PHF2 D+ - - 9 11 6 14 6 14 - - 13 12 5 20 6 19
D- 13 14 8 19 4 23 16 18 11 23 6 28
p value - 0.83 0.98 0.21 - 0.71 0.29 0.55
FANCC D+ - - - - 5 17 5 17 - - - - 7 22 5 24
D- 9 16 5 20 9 21 7 23
p value - - 0.32 0.82 - - 0.61 0.56
PTCH1 D+ - - - - - - 6 8 - - - - - - 9 7
D- 4 29 3 40
p value - - - 0.02* - - - 0.00003*
Abbreviations used are: D+: Deletion positive; D-: Deletion negative; * indicates p value significancePage 7 of 13
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(a) Histogram showing pattern of methylation in the four genesFigure 3
(a) Histogram showing pattern of methylation in the four genes. (b) Representative agarose gels showing methylation 
in PHF2, FANCC, PTCH1 and XPA done by MSRA. H, HpaII digested DNA; M, MspI digested DNA; U, undigested DNA. Con-
trols: A 445-bp fragment of β3A adaptin gene (K1) and 229-bp fragment of RARβ2 exon-1 (K2).
Molecular Cancer 2008, 7:84 http://www.molecular-cancer.com/content/7/1/84expression of these genes in primary tumors was seen in
the following order: FANCC (31.6 ± 36.7) > PHF2 (26.54
± 44.41) > PTCH1 (19.3 ± 27.8). Reduced expression was
noted in nearly 33–40% of the tumors, greater than the
mean fold in reduction of the respective genes [Figure 5;
Additional File 5]. Immunohistochemical analysis
showed both FANCC [Figure 6a–c] and PTCH1 proteins
[Figure 6d–f] to be localized exclusively within the cyto-
plasm. Strong cytoplasmic staining in genes observed in
samples with no alterations (deletion and/or methyla-
tion) of the candidate genes, while moderate to negative
expression was observed in samples harboring genetic
and/or epigenetic alterations. Table 5 indicates significant
association between alterations of FANCC (P = 0.004)
Table 4: Association between methylation of the 4 candidate genes in early- and late-onset BC
Group-A Group-B
PHF2 FANCC PTCH1 XPA PHF2 FANCC PTCH1 XPA
M+ M- M+ M- M+ M- M+ M- M+ M- M+ M- M+ M- M+ M-
PHF2 M+ - - 6 4 2 8 4 6 - - 10 3 7 6 5 8
M- 8 29 13 24 4 33 13 33 14 32 9 37
p value - 0.02* 0.36 0.03* - 0.001* 0.12 0.16
FANCC M+ - - - - 6 8 7 7 - - - - 7 16 7 16
M- 9 24 1 32 14 22 7 29
p value - - 0.29 0.0001* - - 0.51 0.33
PTCH1 M+ - - - - - - 4 11 - - - - - - 9 12
M- 4 28 5 33
p value - - - 0.23 - - - 0.01*
Abbreviations used are: M+: Methylation positive; M-: Methylation negative; * indicates p value significance
Patten of overall alterations in 4 candidate genes at chr9q22.32-22.33Figure 4
Patten of overall alterations in 4 candidate genes at 
chr9q22.32-22.33.
Box plot representing the relative expression level of PHF2, FANCC and PTCH1 gen s done by Q-PCR as shown in they-a isigure 5
Box plot representing the relative expression level of 
PHF2, FANCC and PTCH1 genes done by Q-PCR as 
shown in the y-axis. Each box shows the distribution of 
expression levels from 25th to 75th percentile. The median is 
shown as a line across the box, whereas the '+' is the calcu-
lated mean expression level for the particular subtype. Over-
all, the cases consistently had lower expression of the 
candidate TSGs.Page 9 of 13
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sion as seen by immunohistochemistry. The immunohis-
tochemical analysis of PHF2 was not done due to the lack
of commercially available antibody.
Association with some DNA repair genes
Of the 106 BC samples a subset of 29 group-A and 33
group-B breast samples were further studied to find out
the association between the candidate genes with some
breast cancer susceptibility genes like BRCA1, BRCA2 that
are intermittently associated with breast cancer. Deletion
status of BRCA1 and BRCA2 in the 29 group-A and 33
group-B samples has already been reported [42]. Overall
alterations of FANCC showed significant association with
deletion of BRCA2 in both group-A (P = 0.03) and group-
B (P = 0.02). However, only in group-A, significant asso-
ciation was observed between overall alterations of
PTCH1 and deletion of BRCA1 (P = 0.04) [Additional File
6].
Clinico-pathological association and patient survival
In group-A, both deletion and methylation of PTCH1
were significantly associated with advanced stages. More-
over, its deletion in group-A and methylation in group-B
were significantly associated with higher tumor grades (P
= 0.02) and lymph node metastasis (P = 0.03) respec-
tively. Methylation of XPA also showed significant associ-
ation with lymph node invasion (P = 0.04) in group-A
[Additional Files 7 and 8].
The clinical outcome in the two age groups was investi-
gated for a period of 5 years. The patient follow-up ranged
from 2–60 months in both age groups. The mean and
median follow-up period in group-A was 32 months each
Immunohistochemistry of FANCC and PTCH1 (a-c) FANCC expression patt rn (d-f) PTCH1 expression patternFigure 6
Immunohistochemistry of FANCC and PTCH1 (a-c) 
FANCC expression pattern (d-f) PTCH1 expression 
pattern. BC samples showing high (a and d) or moderate (b 
and e) or low (c and f) expression of FANCC and PTCH1 
genes respectively. Arrow (→) indicates the expression pat-
tern of FANCC and PTCH1 in primary BC. All magnifications 
are at 20×.
Table 5: Immunohistochemical expression of FANCC and PTCH1 with respect to their alterations
FANCC alteration PTCH1 alteration
Sample No. Deletion/Methylation FANCC protein expression Deletion/Methylation PTCH1 protein expression
1186 +/- - -/- +++
374 -/+ - -/+ -
4187 +/- + -/+ -
3266 +/+ - -/- +++
5451 -/- +++ -/- +++
5596 -/- +++ -/+ -
3156 +/+ - -/- +++
4604 +/+ - +/+ -
4131 -/+ ++ +/- -
2490 +/- - -/+ -
2400 +/+ - -/+ ++
796 +/- ++ -/+ -
880 -/- +++ +/+ -
314 +/- ++ +/- ++
5337 +/- - -/- +++
1865 +/+ - -/+ -
4671 -/- +++ +/- +
3025 +/+ - -/+ -
6155 -/+ - -/- +++
1144 -/- +++ -/+ -
P value P = 0.004 * P = 0.001 *
Abbreviations used are: Sample no is patient's registration numberPage 10 of 13
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tively. Log-rank test uncovered statistically significant dif-
ferences in overall patient survival between cases with
presence and absence of any alteration (deletion and/or
methylation) in FANCC (P = 0.005), PTCH1 (P = 0.03)
and XPA (P = < 0.00001) among group-A samples. How-
ever in group-B samples, alterations of only FANCC (P =
0.01) was significantly associated with survival [Figure 7].
Discussion
Previous studies have shown differences in alteration pat-
tern of various chromosomal regions in the development
of early- and late-onset BC [3-6]. To delineate the molec-
ular pathogenesis of BC in the two age groups in detail,
molecular alterations (deletion/methylation) of candi-
date genes PHF2, FANCC, PTCH1 and XPA within
chr.9q22.32-22.33 region were analyzed due to its associ-
ation with a wide variety of tumors including BC. Nearly
91% samples in both groups presented alterations in any
one of the genes. Compared to XPA, overall frequencies of
alterations in PHF2, FANCC and PTCH1 were higher (Fig-
ure 4). This is the first report of its kind. The overall alter-
ations of these genes were differentially associated in the
two age groups and indicated differences in pathogenesis
and adverse prognosis in patients.
Significant association between deletion and methylation
of FANCC in both groups and PTCH1 in group-A only,
suggested them to be candidate TSGs in BC. The concord-
ance between deletion/methylation of these genes with
protein expression also supported this fact. Down-regula-
tion in mRNA expression of these genes were also seen in
MCF-7 and primary BC samples. Deletion, mutation and
down-regulation of FANCC have also been reported in
other malignancies [16-22]. Significant association of
FANCC-XPA methylation in group-A and FANCC-BRCA2
deletion in both age groups supported interlink between
multiple DNA repair pathways. This warrants further anal-
ysis of other members of this repair pathway needs to be
done. The association noted between FANCC alterations
and adverse patient survival in either age group suggests it
as a prognostic marker.
Contrary to previous reports, frequencies of alterations in
PTCH1 in our samples were higher [9]. This may be due
to differences in etiology, ethnicity and techniques used in
our study. Mutations in exon-23 of PTCH1 were reported
in BCC but, no such changes were seen in our samples
[43]. Significant association between PTCH1 and XPA
deletion in both groups as well as between their methyla-
tion in group-B suggested some functional relationship
between hedgehog dependent stem cell renewal pathway
and the NER pathway. Coincident germline mutations in
PTCH1 and BRCA1 genes have been seen in familial BC
and NBCCS [24]. Similarly, correlation between PTCH1
alterations with BRCA1 deletion in group-A suggested its
association with other DNA repair pathways. Poor sur-
vival in group-A patients with PTCH1 alterations indi-
cated its prognostic significance. In PHF2 and XPA no
association was seen between their deletion and methyla-
tion. So, other mechanisms of inactivation such as muta-
tion cannot be ruled out. High deletion along with
significant association of PHF2 methylation with FANCC
methylation in both age groups and XPA methylation in
group-A suggested PHF2 to be a candidate TSGs in BC.
Reduced expression of PHF2 mRNA also supported this
fact. Further analysis of PHF2 is required to assess its role
in tumorigenesis.
Conclusion
Thus it may be concluded that impairment of multiple
DNA repair pathways and PTCH1 associated self-renewal
pathway are necessary for the development of both groups
of BC. However, differential association of these genes
with adverse patient outcome in both groups suggests
their differences in molecular pathogenesis.
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